Perseus Proteomics (TSE:4882) Change In Receivables: 円4.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4882 Perseus Proteomics Inc TSE:4882
54 GF Score
Price 円148.00
GF Value 円442.43
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Perseus Proteomics Change In Receivables?

Perseus Proteomics TSE:4882 +2.07% 54 Change In Receivables is 円4.1 Mil as of Mar. 2026. GuruFocus rates TSE:4882 with a GF Score™ of 54/100 and a GF Value™ of 円442.43 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Perseus Proteomics's change in receivables for the quarter that ended in Mar. 2026 was 円-2.4 Mil. It means Perseus Proteomics's Accounts Receivable increased by 円2.4 Mil from Sep. 2025 to Mar. 2026 .

Perseus Proteomics's change in receivables for the fiscal year that ended in Mar. 2026 was 円4.1 Mil. It means Perseus Proteomics's Accounts Receivable declined by 円4.1 Mil from Mar. 2025 to Mar. 2026 .

Perseus Proteomics's Accounts Receivable for the quarter that ended in Mar. 2026 was 円18.1 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Perseus Proteomics's Days Sales Outstanding for the six months ended in Mar. 2026 was 44.37.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Perseus Proteomics's liquidation value for the six months ended in Mar. 2026 was 円1,126.7 Mil.

Perseus Proteomics  (TSE:4882) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Perseus Proteomics's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=18.123/74.544*91
=44.37

2. In Ben Graham's calculation of liquidation value, Perseus Proteomics's accounts receivable are only considered to be worth 75% of book value:

Perseus Proteomics's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1515.346-405.771+0.75 * 18.123+0.5 * 7.118
=1,126.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics Change In Receivables Related Terms

Perseus Proteomics Change In Receivables Historical Data

* Premium members only.

The historical data trend for Perseus Proteomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics Change In Receivables Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
Get a 7-Day Free Trial Premium Member Only -1.36 0.30 -3.85 -8.55 4.09

Perseus Proteomics Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 5.54 -14.09 6.46 -2.37
TSE:4882
54GF Score
Perseus Proteomics Inc TSE:4882
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perseus Proteomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円4.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円4.1 Mil mean?
Perseus Proteomics (TSE:4882) has a Change In Receivables of 円4.1 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Perseus Proteomics and its competitors.
Is Perseus Proteomics' Change In Receivables too high?
Perseus Proteomics' current Change In Receivables is 円4.1 Mil. Overall, Perseus Proteomics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Change In Receivables compare to LLY and JNJ?
Perseus Proteomics' Change In Receivables of 円4.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Perseus Proteomics and its competitors. Perseus Proteomics's current Change In Receivables is 円4.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円442.43, compared to a current price of 円148.00 — trading 66.5% below its estimated fair value. The current Change In Receivables is 円4.1 Mil. Perseus Proteomics' overall GF Score™ is 54/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Change In Receivables is 円4.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perseus Proteomics (TSE:4882) Overvalued in 2026?

Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued. The current stock price of 円148.00 is trading 66.5% below its estimated GF Value™ of 円442.43. GuruFocus considers Perseus Proteomics to be Significantly Undervalued.

Key valuation signals for TSE:4882:

  • Change In Receivables: 円4.1 Mil
  • GF Value™: 円442.43 vs. price of 円148.00 (66.5% below fair value)
  • GF Score™: 54/100 with 1 warning sign

No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Perseus Proteomics Business Description

Address 30-1 Hakozakicho, Nihonbashi, Chuo-ku, AiNihombashi EAST 3rd floor, Tokyo, JPN, 103-0015
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
54GF Score

Get the complete analysis for TSE:4882

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円148.00
Price
円442.43
GF Value